医学
外科切除术
大疱性表皮松解症
基底细胞
遗传增强
皮肤病科
外科
基因
病理
遗传学
生物
作者
Molly Wallace,Rishob Dasgupta,Karen Cravero,Henry Y. Yang,Andrew P. South,Neda Nikbakht
摘要
This case report describes the use of beremagene geperpavec (B-VEC), the first FDA-approved topical gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), in the treatment of a large surgical defect following excision of a squamous cell carcinoma in a 55-year-old patient with RDEB. After wide local excision, the wound was treated with B-VEC, resulting in complete healing within 7 weeks, with no complications or recurrence at the 10-month follow-up. This novel approach highlights the potential of B-VEC to improve surgical outcomes and wound healing in patients with RDEB.
科研通智能强力驱动
Strongly Powered by AbleSci AI